Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIP1802 vs HGP1705 in Healthy Volunteers
NCT04324905Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esomeprazole + domperidone in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration and Reduced rate from baseline in 24h integrated gastric pH. Started Apr 2020; status: completed.
02
Drugs
esomeprazole + domperidone
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04324905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324905.